YAYaren Alras

Yaren Alras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yaren Alras has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anemone sensu lato (Ranunculaceae): ethnopharmacology, phytochemistry, and pharmacological potential

    by Sarenur Tekiner, Yaren Alras, Rumeysa Berra Karataş, Kaan Zıkşahna, Onur Esen, Yağmur Ekenoğlu Merdan, Murat Ihlamur

    Objectives: To synthesize current knowledge of the taxonomy, ethnopharmacology, phytochemistry, and pharmacological potential of Anemone sensu lato, including lineages historically treated as Pulsatilla and Hepatica, and assess its relevance to natural-product and drug-discovery research. Methods: Literature in Scopus, Web of Science Core Collection, PubMed, and Google Scholar was reviewed through March 2026. Scientific names and synonymy were verified using the International Plant Names Index and World Flora Online. Key findings: Anemone taxa are traditionally used for inflammatory, infectious, painful, and wound-related conditions and contain abundant triterpenoid saponins, alongside flavonoids, phenolic acids, lactone derivatives, and minor metabolites. Triterpenoid saponins are the predominant bioactive class and are associated with antibacterial, antioxidant, anti-inflammatory, anticancer, hepatoprotective, antidiabetic, and tissue-protective effects in preclinical models. Reported mechanisms involve oxidative stress, inflammatory mediators, apoptosis-related pathways, and proliferative signaling. Translation remains limited by taxonomic ambiguity, interspecific chemical variability, insufficient extract standardization, incomplete pharmacokinetic characterization, and inadequate toxicity assessment. Conclusions: Anemone taxa are promising sources of pharmacologically relevant natural products. Rigorous species authentication, standardized phytochemical profiling, harmonized safety evaluation, and clinically relevant models are required before therapeutic development can be advanced.

  • VISTA as a myeloid-centered checkpoint axis in cancer: biology, tumor microenvironment, and therapeutic implications

    by Sarenur Tekiner, Rumeysa Berra Karataş, Yaren Alras, Kaan Zıkşahna, Selim Merdan, Murat Ihlamur

  • Overcoming resistance to immune checkpoint inhibitors in cancer: translational mechanisms, dynamic biomarkers, clinically actionable combination strategies, and comparative checkpoint biology

    by Rumeysa Berra Karataş, Yaren Alras, Sarenur Teki̇nEr, Kaan Zıkşahna, Selim Merdan, Murat Ihlamur

    Immune checkpoint inhibitors (ICIs) have reshaped cancer therapy by restoring antitumor immune activity, yet primary and acquired resistance continue to limit durable clinical benefit. This review integrates the major tumor-intrinsic and tumor-extrinsic mechanisms that drive ICI resistance, including defective antigen presentation, impaired interferon signaling, oncogenic and epigenetic immune escape programs, metabolic rewiring, suppressive myeloid and stromal circuits, abnormal vasculature, and progressive T-cell dysfunction. We discuss these mechanisms in the context of the cancer–immunity cycle and tumor immunotypes, emphasizing how immune-desert, immune-excluded, inflamed-but-suppressed, and adaptive-resistance phenotypes may require different therapeutic strategies. Building on this framework, we evaluate clinically actionable combination approaches, including dual-checkpoint blockade, myeloid and stromal remodeling, radiotherapy or targeted agents to increase tumor antigenicity, DNA damage response–directed combinations, anti-angiogenic strategies, and interventions aimed at preserving or restoring T-cell fitness. Practical considerations for sequencing and patient selection are highlighted according to resistance phenotype, prior ICI exposure, disease tempo, biomarker status, and toxicity risk. We further outline a dynamic biomarker approach that moves beyond single baseline assays by integrating longitudinal tissue and blood-based readouts, including circulating tumor DNA, immune-cell states, soluble immune mediators, T-cell receptor dynamics, and reassessment at progression to guide adaptive therapy. Finally, selected non-oncologic and special clinical contexts, including chronic infections, solid organ transplantation, pre-existing autoimmune disease, and neuroinflammatory or neurodegenerative conditions, are discussed as comparative checkpoint-biology models rather than as separate therapeutic indications. These settings illustrate how chronic antigen exposure, immune exhaustion, tolerance disruption, and immune-related toxicity can inform the understanding of adaptive immune resistance in malignancy. Overall, this review provides a translational framework for matching ICI resistance biology with rational combination strategies and evolving biomarker-guided treatment decisions. Graphical Abstract